Currently, approved CAR-T cell therapy targets are mostly the B cell maturation antigen (BCMA) for multiple myeloma (MM) [8, 9] and the B cell antigen CD19 for various lymphoid malignancies including B-cell leukemias [10–12] and some types of lymphomas [13, 14]. This evidence concerns the gene TNFRSF17 and Miyoshi myopathy.